Physician profile
Roberta Mott
NPI 1164052015
$2,376.42
in general payments reported to CMS, 2019-2025
20 companies · $705 in 2025
The $705 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $509 · 2024: $1,162 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $476.78 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $342.85 | 2023-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $276.88 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.57 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $208.55 | 2023-2025 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $188.45 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $102.03 | 2023-2025 | Rayaldee |
| Amgen INC. | $89.75 | 2024 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $87.90 | 2024-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $71.62 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $51.54 | 2023-2025 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.07 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $44.05 | 2025 | Ozempic |
| Fresenius USA Marketing, INC. | $29.22 | 2024-2025 | Velphoro, Velphoro |
| Shield Therapeutics INC | $27.98 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $24.53 | 2023 | Veltassa, Korsuva |
| Alnylam Pharmaceuticals INC. | $21.63 | 2023 | Amvuttra |
| Pharmacosmos Therapeutics INC. | $20.50 | 2024 | Monoferric |
| Akebia Therapeutics INC | $15.97 | 2024 | Auryxia, Vafseo |
| Ardelyx, INC. | $14.55 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Mott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.